Concepedia

Nathan A. Brooks

NA

Statistics

Publications

22

Citations

889

H-Index

16

Active since

2009

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of Iowa

Eli Lilly (United States)

Moffitt Cancer Center

University of Arizona

Nathan A. Brooks is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, urology, and oncology.

ORCID

Publications per year

2009–2022

22

Publications

22

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer

Ryan L. Steinberg, Lewis J. Thomas, Nathan A. Brooks et al. · The Journal of Urology · 2019 · 182 citations

, , +5

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks et al. · Molecular Cancer Therapeutics · 2013 · 116 citations

, , +13

Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors

Zhigang Wang, William Watt, Nathan A. Brooks et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2010 · 69 citations

, , +13

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design

Justin T. Matulay, Roger Li, Patrick J. Hensley et al. · The Journal of Urology · 2021 · 69 citations

, , +7

IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease

Kirk A. Staschke, Sucai Dong, J. K. Saha et al. · The Journal of Immunology · 2009 · 54 citations · Full text

, , +17

1–5 of 22